Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Solid tumor antigen antibodies bind surface proteins overexpressed on carcinoma, sarcoma or neuroblastoma cells. Zolbetuximab targets claudin 18.2, and enfortumab binds Nectin-4, an adhesion protein that is common in urothelial cancer. Sacituzumab and datopotamab bind trophoblast cell-surface antigen 2 (TROP2), and mirvetuximab binds folate receptor alpha (FRĪ±). Dinutuximab recognizes the disialoganglioside GD2, and labetuzumab binds carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). Many of these antibodies are the targeting component of antibody-drug conjugates used in internalization, payload delivery and cytotoxicity studies.
Synonyms: BAY 1112623
Lupartumab (BAY 1112623) is a monoclonal antibody targeting LYPD3 (C4.4A), designed for the development of the antibody-drug conjugate BAY 1129980. This antibody serves as a precise tool in the synthesis of targeted therapies, potentially enhancing the delivery and efficacy of oncologic treatments.
Anti-CA19-9 Antibody (1116-NS-19-9) is a chimeric monoclonal antibody of the mouse IgG1, Īŗ subclass, specifically designed to target human CA19-9 antigen. For accurate experimental controls, it is recommended to use Mouse IgG1 kappa Isotype Control in conjunction with this antibody to ensure specificity and consistency in results.
Synonyms: SC-003 mAb; SC-Mab003; SC34.28ss1
Tamrintamab, also known as SC-003 mAb, SC-Mab003, or SC34.28ss1, is an antibody-drug conjugate (ADC) specifically designed to target dipeptidase 3 (DPEP3 or MBD3). DPEP3, a glycosyl phosphatidylinositol-anchored metallopeptidase, is notably overexpressed in ovarian tumors. By binding to cells expressing DPEP3, Tamrintamab mediates targeted cytotoxicity, making it a valuable tool for research into the pathophysiology and potential treatments of ovarian cancer.
The Anti-Mesothelin Antibody (YP218) is a chimeric rabbit IgG that specifically targets human Mesothelin. This antibody is designed for precision in detecting and binding to the Mesothelin protein, which is prominently expressed in various forms of cancer, including mesothelioma and ovarian carcinoma. Suitable for a range of research applications, this antibody provides a valuable tool for the study of Mesothelin's role in cancer pathogenesis and potential therapeutic interventions.
Synonyms: Anti-Human F3 Recombinant Antibody
Tisotumab is a recombinant human IgG1 monoclonal antibody and antibody-drug conjugate (ADC) specifically designed to target Tissue Factor (TF), a cell surface glycoprotein frequently overexpressed in various solid tumors. This antibody's specificity for TF makes it a valuable tool for the study of solid tumor pathophysiology and potential therapeutic interventions. Tisotumab's role in targeting and binding to TF allows for precise delivery of cytotoxic agents in the context of cancer research, making it an essential component for studies focused on oncology and tumor biology.
BNC101 is a human-specific monoclonal antibody that targets GPCR-LGR5, also known as GPR49. This antibody is designed for therapeutic use in the management of metastatic colorectal cancer (CRC), leveraging its specificity to bind to the LGR5 receptor, which plays a critical role in cancer stem cell biology and tumor growth. BNC101 holds potential for advancing CRC treatment by selectively targeting and modulating LGR5-expressing cells.
Synonyms: PR-1498487
Samrotamab is a chimeric humanized antibody of the IgG1-Īŗ isotype, specifically designed to target the leucine-rich repeat-containing 15 (LRRC15) protein. This monoclonal antibody binds selectively to LRRC15, a protein expressed in various tumor types, making it a valuable tool for cancer research and therapeutic development.
Synonyms: Anti-Human lymphocyte Ī±4Ī²7 integrin; Humanized Antibody
Vedolizumab, a humanized IgG1 monoclonal antibody, selectively binds to the Ī±4Ī²7 integrin. This targeted mechanism is pivotal in the management of immune responses in the gastrointestinal tract, making it an effective therapeutic option for ulcerative colitis and Crohn's disease.
Synonyms: KM 871; KW 2871
Ecromeximab, also known as KM 871 and KW 2871, is a chimeric monoclonal antibody of the IgG-Īŗ isotype derived from mouse. It specifically targets ganglioside GD3, a sialic acid-containing glycosphingolipid overexpressed in various tumor cells. This antibody is produced in YB2/0 rat hybridoma cells, ensuring a high level of purity and specificity. Ecromeximab is utilized primarily in research focused on the therapeutic targeting of cancers that express ganglioside GD3.
Samatatug is a human monoclonal antibody of the IgG1Īŗ subtype that specifically targets the F3 protein. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.
Synonyms: AB1-11
Anti-CLDN6 Antibody (AB1-11) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CLDN6. This antibody is comprised of an IgG1 heavy chain and a human kappa (huĪŗ) light chain, and exhibits a predicted molecular weight of 78.42 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa, Isotype Control.
Abrilumab is a fully human monoclonal antibody that targets the Ī±4Ī²7 integrin heterodimer with high specificity. This antibody selectively binds to the Ī±4Ī²7 integrin, a critical molecule involved in the pathogenesis of inflammatory bowel diseases (IBD). Abrilumab is utilized primarily in research settings to investigate the underlying mechanisms and potential therapeutic interventions for IBD.
Synonyms: MORAb-003
Farletuzumab (MORAb-003) is a humanized monoclonal antibody that selectively targets and inhibits folate receptor-alpha (FRĪ±), demonstrating high affinity binding. This antibody exerts growth-inhibitory effects on cells that overexpress FRĪ±, making it a valuable tool in oncological research focused on cancers characterized by elevated levels of this receptor.
Synonyms: rhuMAb
Erlizumab is a humanized monoclonal antibody designed to target Integrin beta-2 (ITGB2 / CD18), offering therapeutic potential in the management of hemorrhagic shock. This antibody selectively binds to Integrin Ī²2, a protein involved in leukocyte adhesion and migration, thereby modulating inflammatory responses critical in the pathology of hemorrhagic shock. Erlizumab provides a novel approach to modulate the immune system's response under these critical conditions.
The Anti-SEZ6 Antibody (SC17) is a monoclonal IgG1 antibody targeting the SEZ6 protein. This antibody serves as a primary component in the development of antibody-drug conjugates (ADCs), including the specific ADC product ABBV-011. It is designed for high specificity and affinity in binding to the SEZ6 antigen, making it a valuable tool in targeted therapeutic applications.
Aplitabart is a humanized IgM-Īŗ antibody that specifically targets TNFRSF10B. This monoclonal antibody is designed for precise interaction with the TNFRSF10B receptor, which plays a critical role in the regulation of apoptosis. Aplitabart is utilized primarily in research focused on cancer biology, particularly in studies investigating the mechanisms of programmed cell death and potential therapeutic interventions.
NEO-201 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CEACAM6/CD66c. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 145.48 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended.
Synonyms: CS-1008; Anti-Human TRAIL-R2 Recombinant Antibody
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody that specifically targets Death Receptor 5 (DR5). This antibody facilitates the induction of apoptosis in cancer cells and has demonstrated the ability to inhibit tumor growth in vivo. Tigatuzumab is primarily utilized in cancer research, offering potential insights into therapeutic strategies for targeting apoptotic pathways in oncology.
The Anti-TPBG Antibody (PF-06263507) is a humanized monoclonal antibody, produced in Chinese Hamster Ovary (CHO) cells, designed to specifically target TPBG. This antibody is comprised of a human IgG1 type heavy chain and a human kappa type light chain, with an estimated molecular weight of 145.8 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody serves as a valuable tool for research focused on the biological functions and pathological roles of TPBG.
Synonyms: VB6-845; Anti-Human EpCAM Recombinant Antibody Fab Fragment; 17-1A
Citatuzumab bogatox (VB6-845) is a recombinant immunotoxin consisting of a humanized antibody Fab fragment targeting epithelial cell adhesion molecule (EpCAM) linked to a modified cytotoxin, bouganin. This agent binds selectively to EpCAM-positive cell lines, inducing apoptosis effectively. Citatuzumab bogatox demonstrates robust activity in EpCAM-positive human tumor xenograft models, highlighting its potential for targeted cancer therapy applications.
Synonyms: BMS-986012
Atigotatug is a humanized IgG1Īŗ monoclonal antibody specifically targeting Fucosyl ganglioside GM1. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.
Synonyms: PankoMab
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody designed to specifically recognize a tumor-specific epitope of mucin-1 (TA-MUC1). This antibody demonstrates potent tumor-specific activity through antibody-dependent cell-mediated cytotoxicity (ADCC), making it a valuable tool for targeted cancer therapy research.
Synonyms: BMS-986148 antibody
BMS-986021, also known as BMS-986148 antibody, is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets Mesothelin, a protein frequently overexpressed in various forms of cancer, making it a valuable tool for oncological research. This antibody comprises a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 144.46 kDa. For experiments requiring an isotype control, the Human IgG1 kappa Isotype Control is recommended to accurately assess the antibody's specificity and ensure robust experimental results.
Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular domain of glycoprotein NMB (GPNMB), which is overexpressed in certain human breast cancers and melanomas. This antibody can be conjugated with the cytotoxic drug monomethyl auristatin E to create glembatumumab vedotin, an antibody-drug conjugate (ADC) designed to deliver antitumor agents directly to cancer cells. Glembatumumab vedotin demonstrates significant antitumor activity by exploiting the specificity of the antibody to direct cytotoxic activity to GPNMB-expressing tumor cells, thereby minimizing systemic toxicity. This mechanism positions it as a promising therapeutic option in the treatment of GPNMB-expressing malignancies.
